For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical intraepithelial neoplasia grade 3 (CIN3), vaccination with a replication-incompetent Semliki Forest virus vaccine ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

The phase III, randomized, controlled Papilloma Trial Against Cancer in Young Adults (PATRICIA) showed that the HPV-16/18 vaccine has enhanced immunogenicity when aluminium hydroxide and ...

However, if a woman is found to be HPV positive with a high-risk strand (HPV 16 and/or 18), also referred to as a high-grade lesion, she will then be sent for further testing right away.

Fewer than half of women who tested positive for HPV with negative cytological findings returned for a surveillance co-test within 1 year as recommended, yet more than half of those who received ...

It targets four strains of human papillomavirus (HPV) -- HPV-6, 11, 16, and 18. HPV-16 and HPV-18 account for about 70% of all cervical cancers. HPV-6 and -11 cause about 90% of genital warts.

During the first 16 months after an index positive HPV result, only 43.7% of patients received an initial surveillance test, of whom 18.2% had HPV-negative results and negative intraepithelial ...

Fifty percent of patients with CIN3 had histopathological complete response; 63% had HPV16 clearance. HealthDay News — For patients with human papillomavirus (HPV) type 16 (HPV16)-positive ...